Professor Fidelma Flanagan:

It is going really well. Prior to Covid, we had almost completely integrated and have now fully integrated our age range from 65 to 70-year-olds. Prior to the pandemic, we were offering screening to women aged between 50 and 70. That is evidence based. We follow the science in BreastCheck all the time. The incidence is obviously there in the older age group and we will always look to see whether we should be extending our programme beyond the current age range, which is 50 to 70. If one looks at the evidence, it looks like it is changing. It is dynamic. It looks like there are now conditional recommendations that perhaps we should offer screening to those over 70 and those under 50. We are definitely looking at that. We have been temporarily distracted given Covid and delivering the services but that is definitely on our radar.